---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-085138"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T11:33:01.208774+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# enGene Q2 loss $25.8M ($0.51/shr); cash $251.5M; LEGEND study on track

## Summary
- Net loss $25.8M ($0.51/shr) vs $15.0M ($0.38) YoY; operating expenses $27.1M (up 57%).
- Cash and marketable securities $251.5M expected to fund operations into 2027.
- LEGEND pivotal cohort enrollment on track; BLA filing for detalimogene planned mid-2026.
- EMA indicates data could support Conditional Marketing Authorization for BCG-unresponsive NMIBC.
- Amy Pott appointed Chief Global Commercialization Officer effective May 2025.

## SEC filing metadata
- accession: 0000950170-25-085138
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017025085138/0000950170-25-085138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017025085138/engn-20250612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-085138
- JSON: https://secwatch.observer/filing/0000950170-25-085138.json
- Plain text: https://secwatch.observer/filing/0000950170-25-085138.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.